Hypoxia-induced endoplasmic reticulum stress mediates lenvatinib resistance in hepatocellular carcinoma through the IRE1α-XBP1s-HIF1α pathway Authors: Chong Zhang, Yuxin Jiang, Jiatao Liu, Guoping Sun, Hanqing Yu Published: 2026 ABSTRACT Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally, with a dismal prognosis for advanced patients. Lenvatinib, a first-line anti-angiogenic agent, has improved clinical outcomes, but drug resistance remains a major unmet clinical need. Hypoxia, a hallmark of solid tumors, crosstalks with endoplasmic reticulum stress (ERS), yet their combined role in lenvatinib resistance in HCC remains undefined.Methods: TCGA and GEO datasets were analyzed for ERS-related gene expression and prognostic value. In vitro experiments were conducted in HepG2 and HCCLM3 cells under normoxic (21% O₂) or hypoxic (1% O₂) conditions. Cell viability, apoptosis, migration, and protein expression were assessed via standard assays. siRNA silencing and the ERS inhibitor 4-PBA were used for mechanistic validation.Results: The ERS marker GRP78 was significantly upregulated in HCC tissues and correlated with poor survival. Hypoxia induced ERS in HCC cells, promoting proliferation and migration while attenuating lenvatinib-induced apoptosis. Mechanistically, hypoxia induces activation of the IRE1α-XBP1s-HIF1α axis, and genetic silencing of this axis restores lenvatinib sensitivity. 4-PBA effectively reversed hypoxia-mediated drug resistance.Conclusions : Hypoxia-induced ERS mediates lenvatinib resistance in HCC via the IRE1α-XBP1s-HIF1α pathway. Targeting this axis provides a promising strategy to overcome anti-angiogenic therapy resistance in HCC.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00432-026-06504-x. Introduction Hepatocellular carcinoma (HCC) is the sixth most common malignancy globally and the third leading cause of cancer-related deaths. Its 5-year survival rate is less than 10%, with poor prognosis for advanced-stage patients (Singal et al. 2023). Over 90% of HCC cases occur in the context of chronic liver disease and cirrhosis, and both intrinsic and acquired resistance to conventional therapies, including anti-angiogenic treatments, are the core reasons for therapeutic failure (Ito and Nguyen 2023). Although drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway, such as lenvatinib and bevacizumab, have significantly improved clinical outcomes, the activation of compensatory pro-survival pathways often leads to resistance, limiting their long-term benefits (Nakagawa et al. 2014) Therefore, elucidating the mechanisms of resistance in HCC is crucial for overcoming treatment bottlenecks. Tumor hypoxia, a hallmark feature of the solid tumor microenvironment, drives angiogenesis, metabolic reprogramming, and therapeutic resistance by activating hypoxia-inducible factor 1-alpha (HIF-1α) (Hayashi et al. 2019). Notably, although anti-angiogenic therapies aim to normalize blood vessels, they may exacerbate tumor hypoxia, creating a vicious cycle that promotes resistance development (Jain 2014). This paradox suggests the presence of a complex molecular network in the dynamic regulation of the hypoxic microenvironment. Recent studies have shown significant interactions between endoplasmic reticulum stress (ERS) and the unfolded protein response (UPR) with hypoxic signaling (Cao 2015). In breast cancer models, hypoxia can synergistically enhance the transcription of pro-survival genes mediated by HIF-1α through the activation of the IRE1-XBP1 axis, suggesting the conserved nature of cross-pathway regulatory networks in tumor adaptation (Chen et al. 2014). However, the molecular interactions between hypoxia and ERS and their impact on anti-angiogenic therapy resistance in HCC remain to be fully elucidated. ERS, as a core cellular response to protein folding imbalance, coordinates adaptive survival or pro-apoptotic signals through sensors such as IRE1, PERK, and ATF6 (Walter and Ron 2011). Clinical evidence shows that the abnormal overexpression of ERS markers (such as GRP78) in HCC tissues is closely associated with tumor progression, chemotherapy resistance, and poor prognosis (Gifford and Hill 2018). Studies found that chronic ERS can promote HCC cell proliferation and migration by activating the AKT/mTOR pathway (Yang et al. 2017). Hypoxia further exacerbates ERS by disrupting redox balance and protein folding quality, creating a "hypoxia-ERS" bidirectional regulatory vicious cycle (Wang et al. 2014). Notably, in triple-negative breast cancer, the cleaved, activated form of the ERS sensor IRE1, XBP1s, directly binds to the HIF-1α promoter, enhancing its transcriptional activity (Chen et al. 2014). This suggests that the IRE1-XBP1-HIF1α axis may serve as a central hub for cross-pathway regulation, yet its role in anti-angiogenic therapy resistance in HCC has not been explored. This study aims to investigate the relationship between ERS levels and the survival prognosis of HCC patients, the changes in ERS levels in HCC cells under hypoxic conditions, and the impact of hypoxia-induced ERS on HCC cell proliferation, migration, and apoptosis. Through these investigations, we hope to provide new insights into the pathogenesis of HCC and offer novel strategies and directions to optimize current therapeutic regimens, improve clinical efficacy, and enhance patient prognosis. Methods Bioinformatic analysis UALCAN (https://ualcan.path.uab.edu) was utilized to analyze TCGA data, which integrates transcriptomic, epigenetic, and clinical datasets for comprehensive biomarker exploration. This database, available at https://smuonco.shinyapps.io/THER/, integrates information from the GEO database. Here, we use it to analyze the differences in the expression of molecules related to endoplasmic reticulum stress levels under normal oxygen conditions (21% O2) and hypoxic conditions (1% O2). We downloaded STAR-counts data and corresponding clinical information for HCC from the TCGA database (https://portal.gdc.cancer.gov). We then extracted data in TPM format and performed normalization using the log2(TPM+1) transformation. After retaining samples that included both RNAseq data and clinical information, we ultimately selected 371 samples for further analysis. We utilized the ggstatsplot package in R software to generate the correlation plot for two genes, while the correlation plot for multiple genes was displayed using the pheatmap package in R software. We employed Spearman’s correlation analysis to describe the correlation between quantitative variables that do not follow a normal distribution. A p-value less than 0.05 was considered statistically significant. Cell culture and treatments HepG2 and HCCLM3 cells were purchased from the Shanghai Cell Bank, Chinese Academy of Sciences, and cultured at a density of 1 × 105 cells/cm2 in DMEM (WISENT Inc., Saint-Jean-Baptiste, Quebec, Canada) supplemented with 10% FBS (WISENT Inc., Saint-Jean-Baptiste, Quebec, Canada). Normal cell cultures were maintained in a 37 °C incubator with 5% CO2 and 21% O2, while hypoxic cell cultures were grown under 5% CO2 and 1% O2 in a 37 °C incubator. siRNA (BioScien, Shanghai, China) was used to knock down IRE1, XBP1, and HIF in the cells. TdT-mediated dUTP nick end labelling (TUNEL) staining Apoptosis was detected and quantified using the TUNEL Brighter Apoptosis Detection Kit according to the manufacturer’s instructions (Servicebio, Wuhan, China). Apoptotic cells exhibit bright red staining in the nucleus, whereas non-apoptotic nuclei appear blue. A fluorescence microscope was used to detect fluorescence intensity. Proliferation assays and cell viability analysis The CCK8 reagent (Abbkine, Wuhan, China) is used to detect cell viability. HepG2 and HCCLM3 cells were seeded into 96-well culture plates at densities of 4 × 103 and 3 × 103 cells/well, respectively. After 24 h, lenvatinib (MedChemExpress, Shanghai, China) was added to treat the cells for the corresponding times. Then, 10 μL of CCK8 reagent was added to each well and incubated at 37 °C for 1 h. The absorbance at OD 450 nm was measured using a microplate reader. Apoptosis assays and flow cytometry The Annexin V-FITC/PI apoptosis detection kit (Bestbio, Shanghai, China) was used to assess cell apoptosis. Cell apoptosis was analyzed according to the manufacturer’s instructions. Cells were resuspended in 400 μL of 1X Annexin V binding buffer at a concentration of approximately 1 × 106 cells/mL. Then, 5 μL of Annexin V-FITC staining solution was added to the cell suspension, gently mixed, and incubated in the dark at 2–8 °C for 15 min. After adding 5–10 μL of PI staining solution, the mixture was gently mixed and incubated in the dark at 2–8 °C for 2–5 min. Following this, apoptosis rate was calculated using flow cytometry and scatter plots with CytExpert software. Western blot analysis Cells were lysed with freshly prepared protein lysis buffer (RIPA: phenylmethylsulfonyl fluoride (PMSF) = 100:1) and heated with loading buffer in boiling water. Protein samples were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) at appropriate concentrations and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with a primary antibody and then with a horseradish peroxidase (HRP)-labeled secondary antibody. Rabbit anti-human GRP78 polyclonal antibody (1:1000) was obtained from Cell Signaling Technology, (USA). Mouse anti-human β-actin monoclonal antibody (1:500) was obtained from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd. (China). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (H + L) secondary antibody (1:20,000) and HRP-conjugated goat anti-mouse IgG (H + L) secondary antibody (1:20,000) were purchased from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd. (China). Rabbit anti-human XBP1s monoclonal antibody (1:1000) were purchased from Cell Signaling Technology (USA). Rabbit anti-human IRE1α polyclonal antibody (1:1500) was obtained from Abcam (USA). Cell transfection The cell transfection reagent was purchased from BioScien (Shanghai, China). 1 OD of siRNA was diluted with 125 μL of DEPC water to obtain a 20 μM stock solution. Then, 5 μL of the siRNA stock solution was added to 120 μL of basal culture medium, mixed well, and 6 μL of NB Transfection Reagent was added. The mixture was gently mixed and incubated at room temperature for 10–15 min to form the transfection complex, which was then used for subsequent experimental procedures. Cell migration assay Wound Healing Assay: Cells were seeded in six-well plates and cultured to approximately 90% confluence. A linear scratch was created on the cell monolayer using a sterile 200 μL pipette tip. Images were captured at 0 and 24 h to observe the wound healing process. Transwell Migration Assay: 1 × 105 cells were seeded in the upper chamber of a Transwell insert, with serum-free medium used in the upper chamber as the experimental group. The lower chamber was filled with medium containing 10% fetal bovine serum (FBS) as a chemoattractant. After incubation at 37 °C for 24–48 h, cells that migrated to the underside of the membrane were fixed with 4% paraformaldehyde (Biyuntian, Shanghai, China) and stained with crystal violet (Biyuntian, Shanghai, China). Migrated cells were counted in five random fields under a microscope to determine the migration rate. Statistical analysis Each experiment was performed three times, and a p-value < 0.05 was considered statistically significant. The significance of the difference between two independent groups was analyzed using a t-test, and one-way ANOVA was used for multiple comparisons between more than two groups. Graphs were generated using GraphPad Prism 10.0, PS, and PPT software. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Results HSPA5 is upregulated in HCC and is associated with poor patient prognosis To explore the expression of endoplasmic reticulum (ER) stress-related pathway genes in human hepatocellular carcinoma (HCC) tissues, we utilized bioinformatics tools to analyze gene expression and prognosis data from the TCGA database. Data for HCC were obtained from the TCGA-LIHC project. Our analysis of the TCGA database (Fig. 1A) revealed that HSPA5, which encodes the GRP78 protein, was significantly upregulated in HCC patients (p < 0.001). Moreover, the expression level of HSPA5 was associated with the survival status of HCC patients. Patients with high expression of HSPA5 exhibited significantly worse survival outcomes compared to those with low expression (p = 0.023), as shown in Fig. 1B, where the low-expression group had better survival prognosis.Fig. 1The expression of HSPA5 (GRP78) is elevated in HCC tissues and is associated with poor prognosis in patients. A Using bioinformatics analysis tools, we found that the expression of HSPA5 was upregulated in hepatocellular carcinoma (HCC) patients. B Patients with high HSPA5 expression had worse prognosis. C HIF1A expression was upregulated in HCC patients. D Correlation between HSPA5 (GRP78) and HIF1A (HIF1α) The expression of HSPA5 (GRP78) is elevated in HCC tissues and is associated with poor prognosis in patients. A Using bioinformatics analysis tools, we found that the expression of HSPA5 was upregulated in hepatocellular carcinoma (HCC) patients. B Patients with high HSPA5 expression had worse prognosis. C HIF1A expression was upregulated in HCC patients. D Correlation between HSPA5 (GRP78) and HIF1A (HIF1α) Additionally, we analyzed the expression of HIF1A, which encodes the HIF1α protein, in HCC patients using the TCGA database. We found that HIF1α was significantly upregulated (p < 0.001) in HCC patients compared to normal controls (Fig. 1C). Further analysis of the correlation between HIF1α and GRP78 revealed a positive correlation between the two (Fig. 1D), indicating an association between the ER stress-related pathway and HIF1α in HCC. The endoplasmic reticulum stress level of HCC cells increases under hypoxic conditions We aimed to investigate the endoplasmic reticulum (ER) stress in two cell types under hypoxic (1% O2) and normoxic (21% O2) conditions. Specifically, the two cell types were cultured under different oxygen conditions for 24 h. As shown in the results, in both HepG2 and HCCLM3 cells (Fig. 2A), the expression of the ER stress marker GRP78 was higher under hypoxic conditions than under normoxic conditions, and the difference was statistically significant (p < 0.01) (Fig. 2B). This suggests that the level of ER stress in both HepG2 and HCCLM3 cells is higher under hypoxic conditions compared to normoxic conditions.Fig. 2Hypoxia induces (ER) stress in HCC cells, and the optimal concentration and time of TM treatment. A Upregulation of the ER stress marker (GRP78) under hypoxic conditions. B Quantitative protein analysis under hypoxic and normoxic conditions. (C, E), Western blot and quantitative analysis for the optimal concentration of TM treatment. D, F Western blot and quantitative analysis for the optimal duration of TM treatment. G The proliferation of HCC cells under hypoxic conditions Hypoxia induces (ER) stress in HCC cells, and the optimal concentration and time of TM treatment. A Upregulation of the ER stress marker (GRP78) under hypoxic conditions. B Quantitative protein analysis under hypoxic and normoxic conditions. (C, E), Western blot and quantitative analysis for the optimal concentration of TM treatment. D, F Western blot and quantitative analysis for the optimal duration of TM treatment. G The proliferation of HCC cells under hypoxic conditions In addition, we used tunicamycin (TM) as a positive control to assess the extent of ER stress in liver cancer cells for subsequent experiments. Different concentrations of TM (0, 0.625, 1.25, 2.5, 5, 10 µM) were added to HepG2 cells and incubated for 24 h. We found that the maximum level of ER stress occurred at a concentration of 2.5 µM (Fig. 2C), and the difference was statistically significant (Fig. 2E, p< 0.0001). Subsequently, we treated HepG2 cells with 2.5 µM of TM for different time points (0, 3, 6, 12, 24, 48 h). The results showed that the maximum level of ER stress was reached at 24 h of treatment (Fig. 2D), and the difference was statistically significant (Fig. 2F p< 0.0001). In addition, after 24 h of cell culture, we placed the cells in the logarithmic phase into a hypoxic incubator and observed that the proliferation of cells under hypoxia showed an increasing trend over time (Fig. 2G). Additionally, we evaluated the effect of ER stress induction on HCC cell proliferation by measuring cell viability using the CCK‑8 assay. As shown in the supplementary file (cell viability), TM treatment led to a significant increase in the viability of both HCC cell lines. Hypoxia enhances the proliferation of HCC cells and suppresses their apoptosis Hypoxia promotes the proliferation of HCC cells To investigate the effect of hypoxia on the proliferative capacity of HCC cells, we first treated HepG2 and HCCLM3 with varying concentrations (10–100 µM) of Lenvatinib under hypoxic (1% O2) and normoxic (21% O2) conditions for 24 h. The results showed that after Lenvatinib treatment, HepG2 cells exhibited decreased cell viability in both hypoxic and normoxic conditions. However, under hypoxic conditions, the cell viability of HepG2 was higher compared to cells cultured in normoxic conditions (Fig. 3A). A similar result was observed in HCCLM3 cells (Fig. 3B). This indicates that liver cancer cells in a hypoxic environment maintain higher cell viability after Lenvatinib treatment compared to those in normoxic conditions. The IC50 values for HepG2 and HCCLM3 cells were determined to be 44.6 µM and 33.5 µM, respectively. We then treated HepG2 and HCCLM3 cells with Lenvatinib at their respective IC50 concentrations (44.6 µM for HepG2 and 33.5 µM for HCCLM3) and measured cell viability at different time points. The results showed that, prior to 48 h, the cell viability of liver cancer cells under hypoxic conditions was higher than that of cells in normoxic conditions (Figs. 3C-D). However, as time progressed and approached 48 h, the cell viability of both conditions gradually became comparable. This outcome may be attributed to prolonged Lenvatinib treatment, which caused irreversible damage to the cells, leading to cell death, and ultimately resulted in similar cell viability between the two oxygen environments.Fig. 3Hypoxia enhances the proliferation of HCC cells and suppresses their apoptosis A, B Changes in cell viability of HepG2 and HCCLM3 cells treated with varying concentrations of Lenvatinib under normoxic and hypoxic conditions. C, D Changes in cell viability of HepG2 and HCCLM3 cells treated with Lenvatinib for different time points under normoxic and hypoxic conditions. E, F, Western blot and quantitative analysis of endoplasmic reticulum (ER) stress levels in HepG2 cells under different oxygen concentrations, comparing the TM-only group and the TM + Lenvatinib group. G, H, Western blot and quantitative analysis of ER stress levels in HCCLM3 cells under different oxygen concentrations, comparing the TM-only group and the TM + Lenvatinib group. I, J, Flow cytometry was employed to assess the apoptosis rate and perform quantitative analysis in HepG2 and HCCLM3 cells from the control, lenvatinib, and hypoxia + lenvatinib treatment groups. K, L, ​The apoptotic rates in control, Lenvatinib-treated, and Lenvatinib combination groups were determined by TUNEL assay and subjected to quantitative analysis Hypoxia enhances the proliferation of HCC cells and suppresses their apoptosis A, B Changes in cell viability of HepG2 and HCCLM3 cells treated with varying concentrations of Lenvatinib under normoxic and hypoxic conditions. C, D Changes in cell viability of HepG2 and HCCLM3 cells treated with Lenvatinib for different time points under normoxic and hypoxic conditions. E, F, Western blot and quantitative analysis of endoplasmic reticulum (ER) stress levels in HepG2 cells under different oxygen concentrations, comparing the TM-only group and the TM + Lenvatinib group. G, H, Western blot and quantitative analysis of ER stress levels in HCCLM3 cells under different oxygen concentrations, comparing the TM-only group and the TM + Lenvatinib group. I, J, Flow cytometry was employed to assess the apoptosis rate and perform quantitative analysis in HepG2 and HCCLM3 cells from the control, lenvatinib, and hypoxia + lenvatinib treatment groups. K, L, ​The apoptotic rates in control, Lenvatinib-treated, and Lenvatinib combination groups were determined by TUNEL assay and subjected to quantitative analysis Next, we investigated the effect of Lenvatinib (LEN) on the endoplasmic reticulum (ER) stress levels in HCC under normoxic (21% O2) and hypoxic (1% O2) conditions. HepG2 and HCCLM3 cells were cultured under 21% O2 and 1% O2 for 24 h, respectively, followed by the addition of 2.5 µM Tunicamycin (TM) to each group. Afterward, cells were treated with Lenvatinib at their respective IC50 concentrations for 24 h. The results, (Fig. 3E and G), demonstrated that after Lenvatinib treatment under hypoxic conditions, the expression of GRP78 was significantly higher compared to normoxic conditions in both HepG2 and HCCLM3 cells. Additionally, the TM-only group also showed upregulated ER stress. Further quantification of the GRP78/β-actin ratio (Fig. 3F and H) revealed that under hypoxic conditions, the GRP78/β-actin ratio in HCCLM3 and HepG2 cells treated with different concentrations of Lenvatinib was higher than the corresponding groups under normoxic conditions. These findings suggest that the higher ER stress under hypoxic conditions may be one of the reasons for the increased cell viability of HCC in hypoxia compared to normoxic conditions. Under hypoxic conditions, HCC cells demonstrate enhanced resistance to apoptotic pathways We performed flow cytometry to assess cell apoptosis. Lenvatinib at concentrations of 44.6 µM and 33.5 µM was applied to HCCLM3 and HepG2 cells, respectively, with each cell line cultured under hypoxic and normoxic conditions. Compared to the control group (Fig. 3I), the proportion of apoptotic cells was significantly increased in both HepG2 and HCCLM3 cells treated with lenvatinib, regardless of whether they were cultured in normoxia or hypoxia. Further quantitative analysis of the apoptosis rate (Fig. 3J) revealed that the apoptosis rate of both cell lines was lower under hypoxic conditions (LEN + Hypoxia group) than under normoxic conditions (LEN group), with HepG2 showing (12.7 ± 1.68) % vs (17.27 ± 1.84) %, and HCCLM3 showing (11.48 ± 2.46)% vs (18.17 ± 1.92)%, respectively. These results suggest that lenvatinib induces apoptosis in HCC cells, but its pro-apoptotic effect is diminished under hypoxic conditions. Consistent results were observed using the TUNEL assay, which revealed a decrease in the apoptotic rate in the hypoxia group relative to the lenvatinib group (Fig. 3K, L). In the context of Lenvatinib treatment, the ERS inhibitor 4-PBA promotes apoptosis and reduces cell viability in HCC cells To investigate whether ERS contributes to lenvatinib resistance in hepatocellular carcinoma (HCC) cells under hypoxic conditions, we employed the ER stress inhibitor 4-phenylbutyric acid (4-PBA) to examine subsequent changes in hepatocellular carcinoma cell behavior. Western blot analysis (Fig. 4A-B) demonstrated significantly reduced GRP78 expression in both HepG2 and HCCLM3 cells across 4-PBA-treated, lenvatinib-treated (LEN), and combination treatment (LEN + 4-PBA) groups compared to controls (Con), with the most pronounced decrease observed in the LEN + 4-PBA group (Fig. 4C p < 0.0001). These findings indicate that 4-PBA effectively attenuates ER stress levels in HCC cells. Flow cytometric analysis of apoptosis (Fig. 4F) revealed no statistically significant differences between hypoxia groups and hypoxia + 4-PBA groups in either cell line (HepG2: 5.68 ± 1.41% vs 6.13 ± 1.87%; HCCLM3: 3.53 ± 0.91% vs 4.20 ± 1.01%, p > 0.05; Fig. 4D), suggesting that 4-PBA monotherapy does not independently induce apoptosis. However, significant increases in apoptotic rates were observed when comparing hypoxia + LEN with hypoxia + LEN + 4-PBA groups (HepG2: 13.27 ± 1.83% vs 24.36 ± 4.56%, p < 0.0001; HCCLM3: 13.01 ± 1.29% vs 22.92 ± 2.30%, p < 0.001; Fig. 4D), indicating enhanced drug sensitivity through ER stress inhibition under hypoxic conditions. Consistent with these findings, TUNEL assay revealed a significantly higher apoptotic rate in the hypoxia + lenvatinib + 4-PBA group compared to the hypoxia + lenvatinib group(Fig. 4H), with statistical significance(Fig. 4E).Complementary CCK-8 viability assays corroborated these findings (Fig. 4F). While no significant viability differences emerged between hypoxia and hypoxia + 4-PBA groups, both lenvatinib-treated groups showed marked viability reduction compared to hypoxia controls, with the most substantial decrease occurring in the combination group (hypoxia + LEN + 4-PBA). These data collectively demonstrate that pharmacological inhibition of ER stress potentiates lenvatinib-induced cytotoxicity in hypoxic HCC cells.Fig. 4Under the context of Lenvatinib's action, the ERS inhibitor 4-PBA can promote apoptosis and suppress cell viability in HCC cells. A–C GRP78 protein expression profiles and corresponding quantitative analysis in HepG2 and HCCLM3 cells under different treatment conditions. D, G, Flow cytometry-based apoptosis rates and quantitative assessment in HepG2 and HCCLM3 cells. E, H, The apoptotic rates in HepG2 and HCCLM3 cells were determined by TUNEL assay and subjected to quantitative analysis. F Quantitative analysis of cellular viability in HepG2 and HCCLM3 cells Under the context of Lenvatinib's action, the ERS inhibitor 4-PBA can promote apoptosis and suppress cell viability in HCC cells. A–C GRP78 protein expression profiles and corresponding quantitative analysis in HepG2 and HCCLM3 cells under different treatment conditions. D, G, Flow cytometry-based apoptosis rates and quantitative assessment in HepG2 and HCCLM3 cells. E, H, The apoptotic rates in HepG2 and HCCLM3 cells were determined by TUNEL assay and subjected to quantitative analysis. F Quantitative analysis of cellular viability in HepG2 and HCCLM3 cells Hypoxia-induced ERS promotes cell migration, and ERS inhibitor 4-PBA can attenuate this process To investigate the impact of hypoxia-induced ERS on hepatocellular carcinoma cell migration, we performed complementary scratch wound healing assays and Transwell migration experiments. A low concentration of lenvatinib (2 μM) was selected based on the viability and apoptosis data presented in Fig. 3A and B, which maintains cellular migration capacity without inducing significant cell death. The scratch assay revealed that hypoxia significantly enhanced wound closure rates in both HepG2 and HCCLM3 cells compared to normoxic conditions. Notably, co-treatment with the ER stress inhibitor 4-PBA substantially attenuated this hypoxia-induced migratory acceleration (Fig. 5A), with statistical significance confirmed in quantitative analyses (Fig. 5C).Fig. 5The effect of hypoxia and 4PBA on the migration of HCC cells. A, C, Scratch assay to detect the differences in migration ability of HepG2 and HCCLM3 cells under normal oxygen, hypoxia, and 4PBA treatment, along with quantitative analysis. B, D, Transwell assay to detect the differences in migration ability of HepG2 and HCCLM3 cells under normal oxygen, hypoxia, and 4PBA treatment, along with quantitative analysis The effect of hypoxia and 4PBA on the migration of HCC cells. A, C, Scratch assay to detect the differences in migration ability of HepG2 and HCCLM3 cells under normal oxygen, hypoxia, and 4PBA treatment, along with quantitative analysis. B, D, Transwell assay to detect the differences in migration ability of HepG2 and HCCLM3 cells under normal oxygen, hypoxia, and 4PBA treatment, along with quantitative analysis Consistent results were obtained in Transwell migration assays, where hypoxia exposure markedly increased transmembrane migration capacity of both cell lines. This pro-migratory effect was effectively reversed by 4-PBA administration (Fig. 5B), as evidenced by quantitative comparisons showing statistically significant differences (Fig. 5D). These findings collectively demonstrate that hypoxia-driven ER stress activation promotes migratory behavior in hepatocellular carcinoma cells, while pharmacological inhibition of ER stress effectively counteracts this pathological process. Expression profiles of ERN1 (IRE1α), XBP1 and HIF1A (HIF1α) under normoxic and hypoic conditions, along with their correlative relationships We analyzed the GEO dataset (GSE18494) to evaluate hypoxia-induced expression patterns of ERN1(IRE1α), XBP1, and HIF1A(HIF1α) compared to normoxic conditions (Fig. 6A-C). Quantitative analysis revealed significant upregulation of ERN1 (IRE1α, p < 0.01) and HIF1A (HIF1α, p < 0.05) under hypoxia. Although XBP1 did not reach statistical significance relative to normoxic controls, its expression showed an upward trend (p = 0.86). Subsequent nonparametric Spearman's rank correlation analysis using GEO datasets demonstrated statistically significant monotonic relationships in hepatocellular carcinoma cells. A weak but consistent positive correlation was observed between ERN1 and XBP1 expression (ρ = 0.203, P = 8.52 × 10⁻5; Fig. 6D), with superimposed linear regression analysis (blue line) and 95% confidence intervals (gray band) indicating potential biological synergy. Similarly, XBP1 exhibited a significant correlation with HIF1A (ρ = 0.231, P = 7.27 × 10⁻⁶; Fig. 6E). To further validate the direct association between the ER stress sensor and hypoxic signaling, we analyzed the correlation between ERN1 (IRE1α) and HIF1A (HIF-1α) in the TCGA-LIHC cohort. A significant positive correlation was observed between ERN1 and HIF1A expression (Pearson correlation coefficient = 0.438, P < 0.0001; Fig. 6F), completing the evidence chain for the IRE1α-XBP1s-HIF1α signaling axis. Experimental validation in HepG2 and HCCLM3 cell lines confirmed hypoxia-induced upregulation of IRE1α, XBP1, and HIF1α proteins (Fig. 6G). Quantitative analysis demonstrated statistically significant differences in protein expression levels between hypoxic and normoxic conditions (p < 0.05; Fig. 6H-I). These collective findings suggest that IRE1α-XBP1-HIF1α may constitute a coordinated regulatory pathway responsive to hypoxic stress.Fig. 6Hypoxia-Induced Upregulation of ERN1, XBP1, and HIF1A with Potential Intergene Correlation in Hepatocellular Carcinoma A–C, Differential mRNA expression patterns of ERN1, XBP1, and HIF1A genes under normoxic (21% O2) versus hypoxic (1% O2) conditions. Correlation analyses of gene expression profiles between ERN1 and XBP1 and HIF1A across experimental conditions. D–F. Western blot analysis of IRE1α (encoded by ERN1), XBP1 spliced form (XBP1s), and HIF-1α (encoded by HIF1A) protein levels in HepG2 and HCCLM3 cell lines under normoxic and hypoxic conditions. G Quantitative analysis of IRE1α, XBP1s, and HIF-1α protein expression normalized to β-actin loading control in HepG2 (H) and HCCLM3 (I) cells Hypoxia-Induced Upregulation of ERN1, XBP1, and HIF1A with Potential Intergene Correlation in Hepatocellular Carcinoma A–C, Differential mRNA expression patterns of ERN1, XBP1, and HIF1A genes under normoxic (21% O2) versus hypoxic (1% O2) conditions. Correlation analyses of gene expression profiles between ERN1 and XBP1 and HIF1A across experimental conditions. D–F. Western blot analysis of IRE1α (encoded by ERN1), XBP1 spliced form (XBP1s), and HIF-1α (encoded by HIF1A) protein levels in HepG2 and HCCLM3 cell lines under normoxic and hypoxic conditions. G Quantitative analysis of IRE1α, XBP1s, and HIF-1α protein expression normalized to β-actin loading control in HepG2 (H) and HCCLM3 (I) cells Hypoxia-induced ERS contributes to lenvatinib therapy resistance in HCC cells by activating the IRE1α-XBP1s-HIF-1α pathway The IRE1α-XBP1-HIF-1α axis may mediate the effects of hypoxia-triggered endoplasmic reticulum stress To determine whether hypoxia-induced therapeutic resistance to lenvatinib in tumor cells involves the ​​IRE1α–XBP1s–HIF-1α signaling axis​​, we performed the following experiments. First, HepG2 and HCCLM3 hepatocellular carcinoma cell lines were subjected to transient siRNA-mediated knockdown of ​​IRE1α​​ under hypoxic conditions (1% O2, 24 h). Western blot analysis demonstrated that ​​IRE1α depletion significantly reduced protein expression of both XBP1s and HIF-1α​​ Fig. 7A). Densitometric quantification confirmed statistically significant decreases (Fig. 7B, C), indicating that ​​IRE1α regulates the expression of XBP1s and HIF-1α​​ in hypoxic tumor cells. Subsequently, ​​transient knockdown of XBP1s​​ was performed in the same cell lines. This intervention resulted in a ​​marked reduction of HIF-1α protein levels​​ (Fig. 7D), with statistical significance validated by densitometry (Fig. 7E, F). These findings demonstrate that ​​XBP1s acts downstream of IRE1α and upstream of HIF-1α​​ within this signaling cascade.Collectively, our results establish that ​​hypoxia triggers an IRE1α–XBP1s–HIF-1α signaling axis​​ that mediates adaptive responses in hepatocellular carcinoma cells and contributes to lenvatinib resistance.Fig. 7Hypoxia-induced ERS potentially functions through the IRE1α-XBP1-HIF-1α signaling pathway. A-C Following IRE1α knockdown, protein expression changes and quantification of IRE1α, XBP1, and HIF1α in HepG2 and HCCLM3 cells. D-F Following XBP1 knockdown, protein expression changes and quantification of XBP1 and HIF1α in HepG2 and HCCLM3 cells.​​ G–I, Following HIF1α knockdown, protein expression changes and quantification of HIF1α in HepG2 and HCCLM3 cells.​​ J–M, Following HIF1α knockdown, the apoptotic rate in HepG2 and HCCLM3 cells was analyzed and quantified using flow cytometry and the TUNEL assay.​​ Hypoxia-induced ERS potentially functions through the IRE1α-XBP1-HIF-1α signaling pathway. A-C Following IRE1α knockdown, protein expression changes and quantification of IRE1α, XBP1, and HIF1α in HepG2 and HCCLM3 cells. D-F Following XBP1 knockdown, protein expression changes and quantification of XBP1 and HIF1α in HepG2 and HCCLM3 cells.​​ G–I, Following HIF1α knockdown, protein expression changes and quantification of HIF1α in HepG2 and HCCLM3 cells.​​ J–M, Following HIF1α knockdown, the apoptotic rate in HepG2 and HCCLM3 cells was analyzed and quantified using flow cytometry and the TUNEL assay.​​ Hypoxia-induced ERS promotes therapeutic resistance to lenvatinib in hepatocellular carcinoma cells by targeting HIF-1α To further validate the role of HIF-1α in tumor cell apoptosis, migration, and proliferation, we performed transient knockdown of the HIF1A gene via transfection in HepG2 and HCCLM3 cells under hypoxic conditions. Results demonstrated a significant decrease in HIF-1α protein levels in the knockdown group compared to the control, as evidenced by western blotting (Fig. 7G) and confirmed by statistical analysis (Fig. 7H, I). Following HIF-1α knockdown and treatment with lenvatinib in both the scrambled control siRNA (si-NC) and si-HIF groups, apoptosis was assessed by flow cytometry. Analysis revealed a significantly higher apoptotic rate in the si-HIF group compared to the si-NC group (Fig. 7J, K). Subsequent TUNEL assays yielded consistent results, confirming a significantly higher apoptotic rate in HIF-1α-depleted cells (Fig. 7L, M). We then employed wound-healing and Transwell migration assays to evaluate the impact of HIF1α on tumor cell migration, treating HepG2 and HCCLM3 cells with a low dose of lenvatinib (2 µM) alongside HIF1A knockdown. The wound-healing assay indicated that HIF1A knockdown significantly delayed wound closure in both cell lines compared to the si-NC group (Figs. 8A,B), with this difference being statistically significant (Fig. 8C). Transwell migration assays produced similar results, showing significantly reduced migration in siHIF cells relative to the siNC group (Figs. 8D, E). Furthermore, CCK-8 assays measuring cell viability demonstrated that lenvatinib treatment induced a more pronounced decrease in viability in the si-HIF group compared to the group treated with lenvatinib alone (only si-NC + lenvatinib) (Fig. 8F). Collectively, these results suggest that hypoxia-induced endoplasmic reticulum stress likely promotes tumor cell proliferation, migration, and evasion of apoptosis, potentially conferring resistance to the anti-angiogenic effects of lenvatinib via the IRE1-XBP1-HIF1α signaling axis.Fig. 8HIF-1α promotes cell migration and proliferation. A–C Scratch assay analysis of migration differences between si-NC and si-HIF1α groups in HepG2 and HCC-LM3 cells, with quantitative analysis. D and E Transwell migration assay analysis of migration differences between si-NC and si-HIF1α groups in HepG2 and HCC-LM3 cells, with quantitative analysis. F Quantitative analysis of cell viability in HepG2 and HCC-LM3 cells under the following conditions: Hypoxia; Hypoxia + Lenvatinib (LEN) + si-NC; Hypoxia + LEN + si-HIF1α.​ HIF-1α promotes cell migration and proliferation. A–C Scratch assay analysis of migration differences between si-NC and si-HIF1α groups in HepG2 and HCC-LM3 cells, with quantitative analysis. D and E Transwell migration assay analysis of migration differences between si-NC and si-HIF1α groups in HepG2 and HCC-LM3 cells, with quantitative analysis. F Quantitative analysis of cell viability in HepG2 and HCC-LM3 cells under the following conditions: Hypoxia; Hypoxia + Lenvatinib (LEN) + si-NC; Hypoxia + LEN + si-HIF1α.​ Discussion Hepatocellular carcinoma (HCC)​​ is a prevalent malignant tumor worldwide, posing a significant threat to human health due to its high incidence and mortality rates (Feng and Zhao 2024). ​​Lenvatinib​​, a novel oral multi-target tyrosine kinase inhibitor, has demonstrated significant efficacy in treating unresectable advanced HCC (Zhang et al. 2025). However, the emergence of ​​drug resistance​​ limits its long-term therapeutic benefit (Qin et al. 2024). ​​Hypoxia​​, a common feature of the tumor microenvironment, is closely associated with tumor invasion, metastasis, and drug resistance (Chen et al. 2022). ​​Endoplasmic reticulum stress (ERS)​​ represents a protective cellular response to stress; however, persistent ERS can promote malignant transformation of tumor cells (Cubillos-Ruiz et al. 2017). Hypoxia can induce ERS by disrupting protein folding and trafficking processes and perturbing calcium ion homeostasis within the ER (Yang et al. 2013; Belaidi et al. 2016). Elucidating the mechanistic role of hypoxia-induced ERS in lenvatinib resistance in HCC cells is crucial for developing more effective therapeutic strategies. Analysis of the TCGA and GEO databases revealed that ​​ERS-related genes​​ are upregulated in HCC tissues and correlate with poor patient prognosis. This suggests a significant role for ERS in HCC pathogenesis. This finding aligns with the conclusions of multiple previous studies. For instance, in various cancer studies including lung cancer and breast cancer (Fan et al. 2023; Marciniak 2017), elevated expression of endoplasmic reticulum stress-related proteins has consistently been associated with poor patient prognosis. Experimental results demonstrated that ​​ERS levels were significantly elevated​​ in HCC cell lines (HCCLM3 and HepG2) under hypoxic conditions. Hypoxia activated a cascade of signaling pathways, leading to increased expression of ERS-related proteins. This finding underscores the strong link between hypoxia and ERS, providing a foundation for investigating the role of hypoxia-induced ERS in HCC. From a broader perspective of tumor research, the interplay between endoplasmic reticulum (ER) stress, anti-angiogenesis, and hypoxia is highly complex and closely linked. ER stress plays a crucial role in tumor cells, affecting protein folding and cellular homeostasis, and regulating tumor growth and progression by activating the unfolded protein response (UPR) (Cubillos-Ruiz et al. 2017; Peng et al. 2025). In hypoxic conditions, ER stress works with hypoxia-inducible factor (HIF-1) to enhance tumor cell invasiveness and metastasis (Varone et al. 2021). Additionally, ER stress influences the tumor's angiogenesis by regulating the expression of angiogenic factors such as VEGF (Jiang et al. 2022; Le Mercier et al. 2008). Anti-angiogenic therapy is a crucial strategy in cancer treatment, but its effectiveness is often compromised by hypoxia and ER stress in the tumor microenvironment (Li et al. 2017). Hypoxia not only triggers ER stress but also enhances tumor-related macrophages' function, thereby promoting immune evasion and angiogenesis (Kang et al. 2022). Thus, understanding the mechanisms linking ER stress, anti-angiogenesis, and hypoxia is essential for developing more effective cancer treatment strategies (Schönthal 2013). The core finding of this study is that ​​hypoxia-induced ERS contributes to lenvatinib resistance in HCC cells via the IRE1α-XBP1s-HIF1α pathway​​. We discovered that this pathway promotes HCC cell proliferation and migration while reducing apoptosis under hypoxia. This indicates that the ​​IRE1α-XBP1s-HIF1α axis plays a pivotal role​​ in hypoxia-induced lenvatinib resistance and represents a promising novel target for overcoming this resistance. To further delineate the level of this regulation, we performed supplementary experiments and found that XBP1s knockdown also significantly reduced HIF1A mRNA levels (Supplementary Fig. S1), suggesting that the regulation occurs at the transcriptional level.​ This mechanism parallels findings in triple-negative breast cancer (TNBC), where XBP1s directly binds to HIF1α and enhances its transcriptional activity (Chen et al. 2014). However, it is important to note that while the TNBC study demonstrated direct molecular binding, our current work in HCC establishes this functional relationship primarily through genetic evidence—specifically, knockdown experiments showing that silencing IRE1α or XBP1s significantly reduces HIF1α expression.​ Under hypoxia, cells not only directly induce HIF1α expression but also utilize alternative pathways, potentially because the XBP1s-HIF1α axis maximizes the activation of hypoxia-responsive genes, thereby promoting tumor angiogenesis, metabolic reprogramming, and invasive capacity (Chen et al. 2024; Lee et al. 2017; Wang et al. 2021; Saigusa et al. 2023). Although this study provides important insights into the mechanism by which hypoxia-induced ERS, mediated through the IRE1α-XBP1s-HIF1α pathway, contributes to lenvatinib resistance in HCC cells, several limitations remain. Primarily, the findings are based on in vitro cell experiments and lack validation in in vivo animal models. Specifically, while our data demonstrate that the ER stress inhibitor 4-PBA potentiates lenvatinib-induced cytotoxicity in hypoxic HCC cells, the therapeutic efficacy, optimal dosing, and safety profile of this combination regimen remain to be established in preclinical animal models and subsequent clinical trials. One limitation of this study is that, although we detected the upregulation of total HIF1α protein levels by Western blot, we did not further validate its nuclear translocation process through experiments such as nuclear-cytoplasmic fractionation or immunofluorescence. Future studies will directly confirm the subcellular localization changes of HIF1α to complete this mechanistic pathway. This study preliminarily reveals the role of the IRE1α-XBP1s-HIF1α signaling axis in lenvatinib resistance in HCC. Although TCGA data show a positive correlation between GRP78 and HIF-1α expression, whether HIF-1α directly transcriptionally regulates GRP78 requires further mechanistic investigation. We will explore this scientific question in depth in our future work to complete the regulatory network of this signaling pathway. Furthermore, the ​​crosstalk between the IRE1α-XBP1s-HIF1α pathway and other signaling pathways​​ (e.g., PI3K-Akt, MAPK) remains unclear, potentially hindering a comprehensive understanding of the resistance mechanisms. The study also did not deeply investigate the ​​upstream regulators​​ or ​​downstream effectors​​ of this pathway, precluding the construction of a complete signaling network. Additionally, potential ​​heterogeneity in the response​​ to hypoxia-induced ERS among different HCC cell subpopulations was not thoroughly explored. Our future research will primarily focus on the IRE1–XBP1–HIF1α pathway. We will look into its crosstalk with other signaling pathways and its differing roles in various liver cancer cell subpopulations. Also, we will further confirm its role in in-vivo models and explore its specific mechanisms in tumor development and drug resistance. Our ultimate goal is to provide a more robust and comprehensive theoretical foundation for precision therapy in HCC. Conclusion Collectively, this study elucidates the involvement of hypoxia-induced endoplasmic reticulum stress in lenvatinib therapeutic resistance in hepatocellular carcinoma (HCC) through the IRE1α-XBP1s-HIF1α pathway (Fig. 9). These findings provide a critical theoretical foundation for understanding HCC pathogenesis and developing novel therapeutic strategies. Future research should extend to in vivo models and clinical studies to further explore the underlying molecular mechanisms and identify more effective therapeutic targets and agents, ultimately improving clinical outcomes for HCC patients.Fig. 9Hypoxia-induced ER stress activates UPR signaling to modulate HIF1α-dependent cellular functions. Hypoxia triggers endoplasmic reticulum (ER) stress, leading to unfolded protein accumulation. This activates the unfolded protein response (UPR) pathway, characterized by IRE1α-mediated splicing of XBP1u mRNA into transcriptionally active XBP1s. Hypoxia-induced ER stress concurrently leads to the stabilization and upregulation of HIF1α. The integrated signaling from the UPR and upregulated HIF1α drives pro-survival adaptations, including enhanced cell proliferation and migration, and inhibition of apoptosis Hypoxia-induced ER stress activates UPR signaling to modulate HIF1α-dependent cellular functions. Hypoxia triggers endoplasmic reticulum (ER) stress, leading to unfolded protein accumulation. This activates the unfolded protein response (UPR) pathway, characterized by IRE1α-mediated splicing of XBP1u mRNA into transcriptionally active XBP1s. Hypoxia-induced ER stress concurrently leads to the stabilization and upregulation of HIF1α. The integrated signaling from the UPR and upregulated HIF1α drives pro-survival adaptations, including enhanced cell proliferation and migration, and inhibition of apoptosis Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 170 kb)Supplementary file2 (DOCX 13 kb)Supplementary file3 (DOCX 77 kb) Supplementary file1 (DOCX 170 kb) Supplementary file2 (DOCX 13 kb) Supplementary file3 (DOCX 77 kb)